June 2025

After its 12-month deferral, the EU’s Deforestation Regulation (“EUDR”) is set to apply from December 30, 2025.  Many companies are therefore refocusing EUDR compliance efforts. This blog provides an update on the rules and guidance and key, practical takeaways for companies.

The European Commission (“Commission”) recently provided new and updated materials to support EUDR implementation,

A pair of recent Government Accountability Office (GAO) bid protest decisions addressing impaired objectivity organizational conflicts of interest (OCIs) highlight the fact-specific and highly discretionary nature of a contracting officer’s OCI investigation, as well as the important role that contractors themselves can play in supporting such an investigation.  We discuss these two protests and the

On June 17, the Joint California Policy Working Group on AI Frontier Models (“Working Group”) issued its final report on frontier AI policy, following public feedback on the draft version of the report released in March.  The report describes “frontier models” as the “most capable” subset of foundation models, or a class of general-purpose technologies

Today, the Supreme Court issued its decision in FCC v. Consumers’ Research (No. 24-354), upholding the constitutionality of the Universal Service Fund (“USF”).  The Court in a 6-3 majority opinion penned by Justice Kagan explained that the USF does not violate the “public nondelegation doctrine” or the “private nondelegation doctrine” because Congress provided adequate

Since President Trump issued Executive Order (“E.O.”) 14275, “Restoring Common Sense to Federal Procurement” on April 15, 2025 as part of an effort to remake Federal procurement, the Administration has undertaken a variety of initial steps to implement its so-called “Revolutionary FAR Overhaul” (“RFO”).  These steps include “streamlining” each Part of

This blog was prepared in collaboration with, and was originally published by, the UK BioIndustry Association, here. We are grateful to the UK BioIndustry Association for collaborating on this blog, and for the opportunity to post it here.

What are the UK’s plans to reform data protection law?

After an extended period of legislative

Biotech companies are always searching for new ways to fund the costly and uncertain process of drug development and product launch. Over the past several years, synthetic royalty and drug development financings have become an additional option for fundraising, as traditional equity markets have remained challenging. Covington & Burling’s third annual study tracks these deals